Spherix Neurology

Spherix Global Insights is a leading provider of market research, business intelligence & advisory services to the global neurology & life sciences industry.

[Spherix Neurology @SpherixNeuro]

Spherix's Physician Network offers paid online survey opportunities to qualified U.S. neurologists. Our surveys cover Migraine, MS, ALS, Alzheimer’s Disease, and gMG.

For more information about our paid Physician Network surveys, visit our website:

https://t.co/WusXHubmAX

[Spherix Neurology @SpherixNeuro]

Spherix Global Insights would like to congratulate @pfizer on the launch of Zavzpret™ (zavegepant) for the acute treatment of migraine. Zavzpret is the first and only anti-CGRP nasal spray.
#migraine #pfizer #zavzpret #ubrelvy #reyvow #nurtec #trudhesa

[Spherix Neurology @SpherixNeuro]

Eli Lilly and Company released phase 3 trial data for donanemab with results that suggest more slowing of cognitive decline than has been seen with prior Alzheimer’s therapies, including the recently approved Leqembi (from Eisai/Biogen).

Read More: https://t.co/cVYsLyJUPu

[Spherix Neurology @SpherixNeuro]

Yesterday, the @US_FDA granted full regulatory approval of @biogen / @EisaiUS's Leqembi - now becoming the only approved disease modifying treatment shown to reduce Alzheimer's Disease (AD) progression (slowed cognitive and functional decline) in mild AD patients.

[Spherix Neurology @SpherixNeuro]

Spherix's Neurology team will be attending the @ahsheadache Annual Scientific Meeting (AHS) beginning today and extending until June 18th in Austin, Tx.

We can't wait to see you there!

#ASN #Neurology #Pharma

[Spherix Neurology @SpherixNeuro]

@FiercePharma published a story from the Alzheimer's Association (AA) stating there are currently 187 ongoing clinical trials for Alzheimer's disease, marking the highest number of trials in a year recorded to date.

Read more: https://t.co/s6E2dd2vFl

#Alzhimers #trial #clinical

[Spherix Neurology @SpherixNeuro]

CMS unveiled their intentions to offer extensive coverage for Alzheimer's drugs once the medications receive full approval from the U.S. FDA. Eisai's Leqembi is a potential contender & could obtain full FDA approval as early as this summer.

Read more: https://t.co/dQhp1ZNc8l

[Spherix Neurology @SpherixNeuro]

@TGTherapeutics announced their approval from the European Medicine Agency (EMA) for BRIUMVI (ublituximab-xiiy) to treat adults with relapsing forms of multiple sclerosis (RMS) who have active disease indicated by clinical or imaging features.

Read more: https://t.co/aC3u7PpgMH

[Spherix Neurology @SpherixNeuro]

Sanofi announced positive Phase 2 data of their novel second-generation investigational anti-CD40L antibody, frexalimab, significantly reduced disease activity of patients with relapsing MS & met the primary endpoint.

Read more https://t.co/AqsZL0sUGR

[Spherix Neurology @SpherixNeuro]

Satsuma Pharmaceuticals' announced the FDA accepted to review the new drug application (NDA) for STS101, an innovative and investigational therapeutic product candidate designed for the acute treatment of migraine.

Read more: https://t.co/IhM5xtxSTB

#treatment #trial #NDA #FDA

[Spherix Neurology @SpherixNeuro]

Spherix Global Insights would like to acknowledge World Multiple Sclerosis Day and highlight the importance of connecting Multiple Sclerosis patients to treatments through research and innovation.

#multiplesclerosis

[Spherix Neurology @SpherixNeuro]

@ApellisPharma halted the development of pegcetacoplan, a potential treatment for ALS, following an unsuccessful Phase 2 trial (i.e., MERIDIAN) - The ALS community continues to hope for a clinical breakthrough.

Read more: https://t.co/9KJZUDq9wk

#als #phase2trial #apellis

[Spherix Neurology @SpherixNeuro]

Spherix would like to acknowledge Huntington's Disease Awareness Month and share some resources available:

Cleveland Clinic:
https://t.co/WlDIC2OJyK

Huntington's Disease Society of America:
https://t.co/x60VYMZVgf

Massachusetts General Hospital:
https://t.co/VBIMtFwrZO

[Eric Topol @EricTopol]

One of the most important biomedical studies of 2022 below, on EBV and multiple sclerosis. Today more detailed evidence for the mechanism @ScienceAdvances
https://t.co/zHtUwQ6AC6 @karolinskainst

[Aaron Boster MD @AaronBosterMD]

Exciting updates on Fenebrutinib, a BTKi showing potential in #MS treatment. Recent Phase II results from FENopta trial show promise in preventing new brain lesions. FEN is now being investigated in large Phase 3 trials- & https://t.co/NdqU4HErRd is actively enrolling patients!

[Spherix Neurology @SpherixNeuro]

@Roche announced encouraging findings from the Phase 2 FENopta trial, which examined the effectiveness of the investigational oral medication fenebrutinib in treating adults with RMS. The study met its primary and secondary endpoints.

Read more: https://t.co/nQrujIA7Xg

[Spherix Neurology @SpherixNeuro]

Spherix Global Insights announces the official launch of its new portal after a targeted roll out to select clients over the past few months.

For more details on Spherix's market research reports and interactive dashboard offerings, visit/register here: https://t.co/kMqgqbhdUV

[Spherix Neurology @SpherixNeuro]

@AstraZeneca announced the EU approved Ultomiris (ravulizumab) as the first & only long-acting C5 complement inhibitor for treatment of NMOSD in adult patients with AQP4 antibody-positive status, following the positive recommendation from CHMP.

Read more: https://t.co/HQyXOXzXUV

[Spherix Neurology @SpherixNeuro]

Earlier today, @LundbeckUS & @OtsukaUS announced that the U.S. FDA approved the supplemental New Drug Application (sNDA) for the use of Rexulti (brexpiprazole) in treating agitation associated with dementia in Alzheimer's disease patients.

Read more: https://t.co/iXQUCRfmYl

[LundbeckUS @LundbeckUS]

In partnership with @OtsukaUS, we are proud to announce that today the @FDA approved the first and only pharmacological treatment for agitation associated with dementia due to Alzheimer’s disease. https://t.co/YnJkII58k9

[Spherix Neurology @SpherixNeuro]

Spherix Global Insights acknowledges the importance of ALS Awareness Month.

Resources for patients and families are listed below:
ALS Association:
https://t.co/NizEBEE8Vs

Massachusetts General Hospital: https://t.co/tmuRPoUTg2

ALS Hope Foundation:
https://t.co/TAUMnD9eB6